News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
787,142 Results
Type
Article (64588)
Company Profile (408)
Press Release (722146)
Multimedia
Podcasts (117)
Webinars (14)
Section
Business (222267)
Career Advice (3029)
Deals (38427)
Drug Delivery (129)
Drug Development (88548)
Employer Resources (184)
FDA (17867)
Job Trends (16463)
News (379875)
Policy (38316)
Tag
Academia (2953)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (96)
Alliances (54838)
ALS (106)
Alzheimer's disease (1505)
Antibody-drug conjugate (ADC) (164)
Approvals (17823)
Artificial intelligence (310)
Autoimmune disease (29)
Automation (17)
Bankruptcy (394)
Best Places to Work (12374)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (283)
Bladder cancer (86)
Brain cancer (32)
Breast cancer (311)
Cancer (2486)
Cardiovascular disease (211)
Career advice (2550)
Career pathing (34)
CAR-T (178)
Cell therapy (489)
Cervical cancer (22)
Clinical research (71706)
Collaboration (934)
Company closure (2)
Compensation (586)
Complete response letters (30)
COVID-19 (2856)
CRISPR (50)
C-suite (274)
Cystic fibrosis (110)
Data (2386)
Decentralized trials (2)
Denatured (37)
Depression (56)
Diabetes (301)
Diagnostics (6840)
Digital health (20)
Diversity (8)
Diversity, equity & inclusion (46)
Drug discovery (142)
Drug pricing (132)
Drug shortages (33)
Duchenne muscular dystrophy (104)
Earnings (91676)
Editorial (47)
Employer branding (22)
Employer resources (158)
Events (123322)
Executive appointments (789)
FDA (19304)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (827)
Gene editing (125)
Generative AI (27)
Gene therapy (362)
GLP-1 (859)
Government (5013)
Grass and pollen (6)
Guidances (158)
Healthcare (20443)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (155)
Indications (30)
Infectious disease (3020)
Inflammatory bowel disease (159)
Inflation Reduction Act (11)
Influenza (57)
Intellectual property (103)
Interviews (557)
IPO (17420)
IRA (51)
Job creations (4533)
Job search strategy (2118)
Kidney cancer (11)
Labor market (43)
Layoffs (559)
Leadership (24)
Legal (9658)
Liver cancer (82)
Lung cancer (350)
Lymphoma (162)
Machine learning (9)
Management (63)
Manufacturing (364)
MASH (85)
Medical device (14381)
Medtech (14386)
Mergers & acquisitions (21587)
Metabolic disorders (811)
Multiple sclerosis (90)
NASH (23)
Neurodegenerative disease (119)
Neuropsychiatric disorders (34)
Neuroscience (2130)
NextGen: Class of 2025 (7296)
Non-profit (4947)
Now hiring (41)
Obesity (434)
Opinion (272)
Ovarian cancer (84)
Pain (104)
Pancreatic cancer (90)
Parkinson's disease (165)
Partnered (22)
Patents (260)
Patient recruitment (119)
Peanut (51)
People (63347)
Pharmaceutical (86)
Pharmacy benefit managers (22)
Phase I (22198)
Phase II (31232)
Phase III (23508)
Pipeline (1419)
Policy (181)
Postmarket research (3299)
Preclinical (9724)
Press Release (72)
Prostate cancer (115)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (438)
Real estate (6836)
Recruiting (70)
Regulatory (26011)
Reports (48)
Research institute (2625)
Resumes & cover letters (484)
Rett syndrome (6)
RNA editing (5)
RSV (50)
Schizophrenia (84)
Series A (144)
Series B (93)
Service/supplier (18)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (163)
Sponsored (34)
Startups (4040)
State (2)
Stomach cancer (16)
Supply chain (75)
Tariffs (56)
The Weekly (78)
Vaccines (819)
Venture capitalists (45)
Weight loss (307)
Women's health (39)
Worklife (20)
Date
Today (183)
Last 7 days (1029)
Last 30 days (3281)
Last 365 days (34636)
2025 (12681)
2024 (37400)
2023 (42253)
2022 (53610)
2021 (58290)
2020 (57104)
2019 (50388)
2018 (38239)
2017 (35904)
2016 (36403)
2015 (42174)
2014 (36585)
2013 (31821)
2012 (33929)
2011 (34488)
2010 (33122)
Location
Africa (1019)
Alabama (61)
Alaska (7)
Arizona (258)
Arkansas (14)
Asia (45727)
Australia (7677)
California (6652)
Canada (2108)
China (580)
Colorado (286)
Connecticut (304)
Delaware (167)
Europe (102707)
Florida (982)
Georgia (223)
Hawaii (1)
Idaho (61)
Illinois (609)
India (30)
Indiana (341)
Iowa (11)
Japan (177)
Kansas (109)
Kentucky (26)
Louisiana (14)
Maine (71)
Maryland (981)
Massachusetts (5022)
Michigan (239)
Minnesota (429)
Mississippi (2)
Missouri (91)
Montana (31)
Nebraska (26)
Nevada (69)
New Hampshire (68)
New Jersey (1876)
New Mexico (30)
New York (1871)
North Carolina (1118)
North Dakota (9)
Northern California (2892)
Ohio (223)
Oklahoma (15)
Oregon (41)
Pennsylvania (1462)
Puerto Rico (14)
Rhode Island (34)
South America (1419)
South Carolina (26)
South Dakota (1)
Southern California (2486)
Tennessee (107)
Texas (984)
United States (25230)
Utah (199)
Virginia (163)
Washington D.C. (70)
Washington State (590)
West Virginia (3)
Wisconsin (68)
787,142 Results for "dr reddy s laboratories inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
March 18, 2025
·
11 min read
Business
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
Alvotech (NASDAQ: ALVO) and Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia® and Xgeva® (denosumab).
May 21, 2024
·
14 min read
Dr. Reddy’s Laboratories launches Versavo® (bevacizumab) in the UK
Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® in the United Kingdom.
March 19, 2024
·
5 min read
Press Releases
Dr. Reddy’s Q3 & 9MFY25 Financial Results
January 24, 2025
·
19 min read
Business
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
Alvotech and Dr. Reddy’s Laboratories today announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia® and Xgeva® (denosumab).
May 21, 2024
·
14 min read
Business
Dr. Reddy’s Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
Dr. Reddy’s Laboratories Ltd., announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council.
May 28, 2024
·
5 min read
Press Releases
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
February 6, 2025
·
7 min read
Dr. Reddy’s Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
Dr. Reddy’s Laboratories Ltd. today announced its launch of Doxycycline Capsules, 40 mg* in the U.S. market, a therapeutic generic equivalent of ORACEA® (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA).
May 3, 2024
·
3 min read
Business
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
May 7, 2024
·
21 min read
Business
Pharmazz Inc. and Dr. Reddy’s Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company developing and commercializing drug products to treat critically ill patients, announced that it has entered into a license agreement with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), a global pharmaceutical company, to commercialize a first-in-class innovative drug Centhaquine in India.
March 22, 2024
·
5 min read
1 of 78,715
Next
